Health Care & Life Sciences » Pharmaceuticals | Karolinska Development AB

Karolinska Development AB | Cash Flow

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Other Funds
-
-
-
-
2,628.00
Funds from Operations
51,151.00
44,263.00
42,554.00
28,519.00
34,430.00
28,414
Changes in Working Capital
3,691.00
11,058.00
15,795.00
5,186.00
3,224.00
42,138
Net Operating Cash Flow
47,460.00
55,321.00
58,349.00
23,333.00
31,206.00
13,724
Capital Expenditures
635.00
-
147,382.00
-
-
Purchase/Sale of Investments
3,909.00
37,354.00
119,292.00
14,339.00
42,537.00
Net Investing Cash Flow
24,476.00
53,066.00
266,674.00
14,339.00
42,537.00
Issuance/Reduction of Debt, Net
-
22,858.00
364,001.00
-
-
Net Financing Cash Flow
2,483.00
85,949.00
331,727.00
7.00
2,628.00
Net Change in Cash
74,419.00
22,438.00
6,704.00
8,987.00
8,703.00
Free Cash Flow
48,095.00
55,321.00
205,731.00
23,333.00
31,206.00
Change in Capital Stock
2,483.00
63,091.00
32,274.00
7.00
-
Other Uses
27,750.00
15,712.00
-
-
-

About Karolinska Development AB

View Profile
Address
Tomtebodavägen 23A
Solna AB 171 65
Sweden
Employees -
Website http://www.karolinskadevelopment.com
Updated 07/08/2019
Karolinska Development AB engages in the investment in pharmaceutical business. It invests in companies that develop medical innovations, specialty care products and orphan drugs for patients suffering from life-threatening and serious debilitating conditions. Its funds are obtained from independent investors and shareholders by issuing and selling shares and interest-bearing instruments.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.